👋 Welcome to the 53rd edition of Deep Tech Catalyst, the channel by The Scenarionist where science meets venture!
Products and companies may straddle the boundaries between HealthTech and MedTech, creating a gray area. However, understanding this distinction is crucial when planning the regulatory path, go-to-market strategy, distribution, and ultimately, the type of VC funds involved.
In this episode, we are thrilled to welcome Andrew Rubenstein, Founding Partner at Shorewind Capital. He will help us to pinpoint what makes these two paths different, highlight best practices for HealthTech go-to-market strategies and distribution tactics, and explain how to avoid the most common pitfalls in the early stages.
Key Themes Covered:
🏥 Understanding The Line Between HealthTech and MedTech
🩻 Emerging Trends: Preventive Care and AI
⛔️ A Common Pitfall: Shifting from Consumer to Traditional Healthcare
🤝 Core Team Skillset in HealthTech vs MedTech
🚀 3 Distribution and Go-to-Market Strategies in HealthTech
⏱️ Timelines and VC Expectations in HealthTech vs. MedTech Startups









